12 research outputs found
Author Correction: HAWC observations of the acceleration of very-high-energy cosmic rays in the Cygnus Cocoon (Nature Astronomy, (2021), 5, 5, (465-471), 10.1038/s41550-021-01318-y)
No full textA Correction to this paper has been published: https://doi.org/10.1038/s41550-021-01361-9
Author Correction: HAWC observations of the acceleration of very-high-energy cosmic rays in the Cygnus Cocoon
No full textThe Single-Phase ProtoDUNE Technical Design Report
No full textProtoDUNE-SP is the single-phase DUNE Far Detector prototype that is under
construction and will be operated at the CERN Neutrino Platform (NP) starting
in 2018. ProtoDUNE-SP, a crucial part of the DUNE effort towards the
construction of the first DUNE 10-kt fiducial mass far detector module (17 kt
total LAr mass), is a significant experiment in its own right. With a total
liquid argon (LAr) mass of 0.77 kt, it represents the largest monolithic
single-phase LArTPC detector to be built to date. It's technical design is
given in this report.Comment: 165 pages, fix references, author list and minor number
Supernova neutrino burst detection with the deep underground neutrino experiment: DUNE Collaboration
No full textThe deep underground neutrino experiment (DUNE), a 40-kton underground liquid argon time projection chamber experiment, will be sensitive to the electron-neutrino flavor component of the burst of neutrinos expected from the next Galactic core-collapse supernova. Such an observation will bring unique insight into the astrophysics of core collapse as well as into the properties of neutrinos. The general capabilities of DUNE for neutrino detection in the relevant few- to few-tens-of-MeV neutrino energy range will be described. As an example, DUNE’s ability to constrain the νe spectral parameters of the neutrino burst will be considered. © 2021, The Author(s)
Long-baseline neutrino oscillation physics potential of the DUNE experiment: DUNE Collaboration
No full textThe sensitivity of the Deep Underground Neutrino Experiment (DUNE) to neutrino oscillation is determined, based on a full simulation, reconstruction, and event selection of the far detector and a full simulation and parameterized analysis of the near detector. Detailed uncertainties due to the flux prediction, neutrino interaction model, and detector effects are included. DUNE will resolve the neutrino mass ordering to a precision of 5σ, for all δCP values, after 2 years of running with the nominal detector design and beam configuration. It has the potential to observe charge-parity violation in the neutrino sector to a precision of 3σ (5σ) after an exposure of 5 (10) years, for 50% of all δCP values. It will also make precise measurements of other parameters governing long-baseline neutrino oscillation, and after an exposure of 15 years will achieve a similar sensitivity to sin 22 θ13 to current reactor experiments. © 2020, The Author(s)
Long-baseline neutrino oscillation physics potential of the DUNE experiment: DUNE Collaboration
No full text© 2020, The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. WSU authors: Meyer, H.; Muether, M.; Solomey, N. The complete list includes: Abi, B.; Acciarri, R.; Acero, M.A.; Adamov, G.; Adams, D.; Adinolfi, M.; Ahmad, Z.; Ahmed, J.; Alion, T.; Monsalve, S.A.; Alt, C.; Anderson, J.; Andreopoulos, C.; Andrews, M.P.; Andrianala, F.; Andringa, S.; Ankowski, A.; Antonova, M.; Antusch, S.; Aranda-Fernandez, A.; Ariga, A.; Arnold, L.O.; Arroyave, M.A.; Asaadi, J.; Aurisano, A.; Aushev, V.; Autiero, D.; Azfar, F.; Back, H.; Back, J.J.; Backhouse, C.; Baesso, P.; Bagby, L.; Bajou, R.; Balasubramanian, S.; Baldi, P.; Bambah, B.; Barao, F.; Barenboim, G.; Barker, G.J.; Barkhouse, W.; Barnes, C.; Barr, G.; Monarca, J.B.; Barros, N.; Barrow, J.L.; Bashyal, A.; Basque, V.; Bay, F.; Alba, J.L.B.; Beacom, J.F.; Bechetoille, E.; Behera, B.; Bellantoni, L.; Bellettini, G.; Bellini, V.; Beltramello, O.; Belver, D.; Benekos, N.; Neves, F.B.; Berger, J.; Berkman, S.; Bernardini, P.; Berner, R.M.; Berns, H.; Bertolucci, S.; Betancourt, M.; Bezawada, Y.; Bhattacharjee, M.; Bhuyan, B.; Biagi, S.; Bian, J.; Biassoni, M.; Biery, K.; Bilki, B.; Bishai, M.; Bitadze, A.; Blake, A.; Siffert, B.B.; Blaszczyk, F.D.M.; Blazey, G.C.; Blucher, E.; Boissevain, J.; Bolognesi, S.; Bolton, T.; Bonesini, M.; Bongrand, M.; Bonini, F.; Booth, A.; Booth, C.; Bordoni, S.; Borkum, A.; Boschi, T.; Bostan, N.; Bour, P.; Boyd, S.B.; Boyden, D.; Bracinik, J.; Braga, D.; Brailsford, D.; Brandt, A.; Bremer, J.; Brew, C.; Brianne, E.; Brice, S.J.; Brizzolari, C.; Bromberg, C.; Brooijmans, G.; Brooke, J.; Bross, A.; Brunetti, G.; Buchanan, N.; Budd, H.; Caiulo, D.; Calafiura, P.; Calcutt, J.; Calin, M.; Calvez, S.; Calvo, E.; Camilleri, L.; Caminata, A.; Campanelli, M.; Caratelli, D.; Carini, G.; Carlus, B.; Carniti, P.; Terrazas, I.C.; Carranza, H.; Castillo, A.; Castromonte, C.; Cattadori, C.; Cavalier, F.; Cavanna, F.; Centro, S.; Cerati, G.; Cervelli, A.; Villanueva, A.C.; Chalifour, M.; Chang, C.; Chardonnet, E.; Chatterjee, A.; Chattopadhyay, S.; Chaves, J.; Chen, H.; Chen, M.; Chen, Y.; Cherdack, D.; Chi, C.; Childress, S.; Chiriacescu, A.; Cho, K.; Choubey, S.; Christensen, A.; Christian, D.; Christodoulou, G.; Church, E.; Clarke, P.; Coan, T.E.; Cocco, A.G.; Coelho, J.A.B.; Conley, E.; Conrad, J.M.; Convery, M.; Corwin, L.; Cotte, P.; Cremaldi, L.; Cremonesi, L.; Crespo-Anadón, J.I.; Cristaldo, E.; Cross, R.; Cuesta, C.; Cui, Y.; Cussans, D.; Dabrowski, M.; Motta, H.; Da Silva Peres, L.; David, C.; David, Q.; Davies, G.S.; Davini, S.; Dawson, J.; De, K.; De Almeida, R.M.; Debbins, P.; De Bonis, I.; Decowski, M.P.; de Gouvêa, A.; De Holanda, P.C.; De Icaza Astiz, I.L.; Deisting, A.; De Jong, P.; Delbart, A.; Delepine, D.; Delgado, M.; Dell’Acqua, A.; De Lurgio, P.; de Mello Neto, J.R.T.; DeMuth, D.M.; Dennis, S.; Densham, C.; Deptuch, G.; De Roeck, A.; De Romeri, V.; De Vries, J.J.; Dharmapalan, R.; Dias, M.; Diaz, F.; Díaz, J.S.; Domizio, S.D.; Giulio, L.D.; Ding, P.; Noto, L.D.; Distefano, C.; Diurba, R.; Diwan, M.; Djurcic, Z.; Dokania, N.; Dolinski, M.J.; Domine, L.; Douglas, D.; Drielsma, F.; Duchesneau, D.; Duffy, K.; Dunne, P.; Durkin, T.; Duyang, H.; Dvornikov, O.; Dwyer, D.A.; Dyshkant, A.S.; Eads, M.; Edmunds, D.; Eisch, J.; Emery, S.; Ereditato, A.; Escobar, C.O.; Sanchez, L.E.; Evans, J.J.; Ewart, E.; Ezeribe, A.C.; Fahey, K.; Falcone, A.; Farnese, C.; Farzan, Y.; Felix, J.; Fernandez-Martinez, E.; Menendez, P.F.; Ferraro, F.; Fields, L.; Filkins, A.; Filthaut, F.; Fitzpatrick, R.S.; Flanagan, W.; Fleming, B.; Flight, R.; Fowler, J.; Fox, W.; Franc, J.; Francis, K.; Franco, D.; Freeman, J.; Freestone, J.; Fried, J.; Friedland, A.; Fuess, S.; Furic, I.; Furmanski, A.P.; Gago, A.; Gallagher, H.; Gallego-Ros, A.; Gallice, N.; Galymov, V.; Gamberini, E.; Gamble, T.; Gandhi, R.; Gandrajula, R.; Gao, S.; Garcia-Gamez, D.; García-Peris, M.Á.; Gardiner, S.; Gastler, D.; Ge, G.; Gelli, B.; Gendotti, A.; Gent, S.; Ghorbani-Moghaddam, Z.; Gibin, D.; Gil-Botella, I.; Girerd, C.; Giri, A.K.; Gnani, D.; Gogota, O.; Gold, M.; Gollapinni, S.; Gollwitzer, K.; Gomes, R.A.; Bermeo, L.V.G.; Fajardo, L.S.G.; Gonnella, F.; Gonzalez-Cuevas, J.A.; Goodman, M.C.; Goodwin, O.; Goswami, S.; Gotti, C.; Goudzovski, E.; Grace, C.; Graham, M.; Gramellini, E.; Gran, R.; Granados, E.; Grant, A.; Grant, C.; Gratieri, D.; Green, P.; Green, S.; Greenler, L.; Greenwood, M.; Greer, J.; Griffith, W.C.; Groh, M.; Grudzinski, J.; Grzelak, K.; Gu, W.; Guarino, V.; Guenette, R.; Guglielmi, A.; Guo, B.; Guthikonda, K.K.; Gutierrez, R.; Guzowski, P.; Guzzo, M.M.; Gwon, S.; Habig, A.; Hackenburg, A.; Hadavand, H.; Haenni, R.; Hahn, A.; Haigh, J.; Haiston, J.; Hamernik, T.; Hamilton, P.; Han, J.; Harder, K.; Harris, D.A.; Hartnell, J.; Hasegawa, T.; Hatcher, R.; Hazen, E.; Heavey, A.; Heeger, K.M.; Heise, J.; Hennessy, K.; Henry, S.; Morquecho, M.A.H.; Herner, K.; Hertel, L.; Hesam, A.S.; Hewes, J.; Higuera, A.; Hill, T.; Hillier, S.J.; Himmel, A.; Hoff, J.; Hohl, C.; Holin, A.; Hoppe, E.; Horton-Smith, G.A.; Hostert, M.; Hourlier, A.; Howard, B.; Howell, R.; Huang, J.; Huang, J.; Hugon, J.; Iles, G.; Ilic, N.; Iliescu, A.M.; Illingworth, R.; Ioannisian, A.; Itay, R.; Izmaylov, A.; James, E.; Jargowsky, B.; Jediny, F.; Jesùs-Valls, C.; Ji, X.; Jiang, L.; Jiménez, S.; Jipa, A.; Joglekar, A.; Johnson, C.; Johnson, R.; Jones, B.; Jones, S.; Jung, C.K.; Junk, T.; Jwa, Y.; Kabirnezhad, M.; Kaboth, A.; Kadenko, I.; Kamiya, F.; Karagiorgi, G.; Karcher, A.; Karolak, M.; Karyotakis, Y.; Kasai, S.; Kasetti, S.P.; Kashur, L.; Kazaryan, N.; Kearns, E.; Keener, P.; Kelly, K.J.; Kemp, E.; Ketchum, W.; Kettell, S.H.; Khabibullin, M.; Khotjantsev, A.; Khvedelidze, A.; Kim, D.; King, B.; Kirby, B.; Kirby, M.; Klein, J.; Koehler, K.; Koerner, L.W.; Kohn, S.; Koller, P.P.; Kordosky, M.; Kosc, T.; Kose, U.; Kostelecký, V.A.; Kothekar, K.; Krennrich, F.; Kreslo, I.; Kudenko, Y.; Kudryavtsev, V.A.; Kulagin, S.; Kumar, J.; Kumar, R.; Kuruppu, C.; Kus, V.; Kutter, T.; Lambert, A.; Lande, K.; Lane, C.E.; Lang, K.; Langford, T.; Lasorak, P.; Last, D.; Lastoria, C.; Laundrie, A.; Lawrence, A.; Lazanu, I.; LaZur, R.; Le, T.; Learned, J.; LeBrun, P.; Miotto, G.L.; Lehnert, R.; de Oliveira, M.A.L.; Leitner, M.; Leyton, M.; Li, L.; Li, S.; Li, S.W.; Li, T.; Li, Y.; Liao, H.; Lin, C.S.; Lin, S.; Lister, A.; Littlejohn, B.R.; Liu, J.; Lockwitz, S.; Loew, T.; Lokajicek, M.; Lomidze, I.; Long, K.; Loo, K.; Lorca, D.; Lord, T.; LoSecco, J.M.; Louis, W.C.; Luk, K.B.; Luo, X.; Lurkin, N.; Lux, T.; Luzio, V.P.; MacFarland, D.; Machado, A.A.; Machado, P.; Macias, C.T.; Macier, J.R.; Maddalena, A.; Madigan, P.; Magill, S.; Mahn, K.; Maio, A.; Maloney, J.A.; Mandrioli, G.; Maneira, J.; Manenti, L.; Manly, S.; Mann, A.; Manolopoulos, K.; Plata, M.M.; Marchionni, A.; Marciano, W.; Marfatia, D.; Mariani, C.; Maricic, J.; Marinho, F.; Marino, A.D.; Marshak, M.; Marshall, C.; Marshall, J.; Marteau, J.; Martin-Albo, J.; Martinez, N.; Caicedo, D.A.M.; Martynenko, S.; Mason, K.; Mastbaum, A.; Masud, M.; Matsuno, S.; Matthews, J.; Mauger, C.; Mauri, N.; Mavrokoridis, K.; Mazza, R.; Mazzacane, A.; Mazzucato, E.; McCluskey, E.; McConkey, N.; McFarland, K.S.; McGrew, C.; McNab, A.; Mefodiev, A.; Mehta, P.; Melas, P.; Mellinato, M.; Mena, O.; Menary, S.; Mendez, H.; Menegolli, A.; Meng, G.; Messier, M.D.; Metcalf, W.; Mewes, M.; Meyer, H.; Miao, T.; Michna, G.; Miedema, T.; Migenda, J.; Milincic, R.; Miller, W.; Mills, J.; Milne, C.; Mineev, O.; Miranda, O.G.; Miryala, S.; Mishra, C.S.; Mishra, S.R.; Mislivec, A.; Mladenov, D.; Mocioiu, I.; Moffat, K.; Moggi, N.; Mohanta, R.; Mohayai, T.A.; Mokhov, N.; Molina, J.; Bueno, L.M.; Montanari, A.; Montanari, C.; Montanari, D.; Zetina, L.M.M.; Moon, J.; Mooney, M.; Moor, A.; Moreno, D.; Morgan, B.; Morris, C.; Mossey, C.; Motuk, E.; Moura, C.A.; Mousseau, J.; Mu, W.; Mualem, L.; Mueller, J.; Muether, M.; Mufson, S.; Muheim, F.; Muir, A.; Mulhearn, M.; Muramatsu, H.; Murphy, S.; Musser, J.; Nachtman, J.; Nagu, S.; Nalbandyan, M.; Nandakumar, R.; Naples, D.; Narita, S.; Navas-Nicolás, D.; Nayak, N.; Nebot-Guinot, M.; Necib, L.; Negishi, K.; Nelson, J.K.; Nesbit, J.; Nessi, M.; Newbold, D.; Newcomer, M.; Newhart, D.; Nichol, R.; Niner, E.; Nishimura, K.; Norman, A.; Norrick, A.; Northrop, R.; Novella, P.; Nowak, J.A.; Oberling, M.; Campo, A.O.D.; Olivier, A.; Onel, Y.; Onishchuk, Y.; Ott, J.; Pagani, L.; Pakvasa, S.; Palamara, O.; Palestini, S.; Paley, J.M.; Pallavicini, M.; Palomares, C.; Pantic, E.; Paolone, V.; Papadimitriou, V.; Papaleo, R.; Papanestis, A.; Paramesvaran, S.; Parke, S.; Parsa, Z.; Parvu, M.; Pascoli, S.; Pasqualini, L.; Pasternak, J.; Pater, J.; Patrick, C.; Patrizii, L.; Patterson, R.B.; Patton, S.J.; Patzak, T.; Paudel, A.; Paulos, B.; Paulucci, L.; Pavlovic, Z.; Pawloski, G.; Payne, D.; Pec, V.; Peeters, S.J.M.; Penichot, Y.; Pennacchio, E.; Penzo, A.; Peres, O.L.G.; Perry, J.; Pershey, D.; Pessina, G.; Petrillo, G.; Petta, C.; Petti, R.; Piastra, F.; Pickering, L.; Pietropaolo, F.; Pillow, J.; Pinzino, J.; Plunkett, R.; Poling, R.; Pons, X.; • Poonthottathil, N.; Pordes, S.; Potekhin, M.; Potenza, R.; Potukuchi, B.V.K.S.; Pozimski, J.; Pozzato, M.; Prakash, S.; Prakash, T.; Prince, S.; Prior, G.; Pugnere, D.; Qi, K.; Qian, X.; Raaf, J.L.; Raboanary, R.; Radeka, V.; Rademacker, J.; Radics, B.; Rafique, A.; Raguzin, E.; Rai, M.; Rajaoalisoa, M.; Rakhno, I.; Rakotondramanana, H.T.; Rakotondravohitra, L.; Ramachers, Y.A.; Rameika, R.; Delgado, M.A.R.; Ramson, B.; Rappoldi, A.; Raselli, G.; Ratoff, P.; Ravat, S.; Razafinime, H.; Real, J.S.; Rebel, B.; Redondo, D.; Reggiani-Guzzo, M.; Rehak, T.; Reichenbacher, J.; Reitzner, S.D.; Renshaw, A.; Rescia, S.; Resnati, F.; Reynolds, A.; Riccobene, G.; Rice, L.C.J.; Rielage, K.; Rigaut, Y.; Rivera, D.; Rochester, L.; Roda, M.; Rodrigues, P.; Alonso, M.J.R.; Rondon, J.R.; Roeth, A.J.; Rogers, H.; Rosauro-Alcaraz, S.; Rossella, M.; Rout, J.; Roy, S.; Rubbia, A.; Rubbia, C.; Russell, B.; Russell, J.; Ruterbories, D.; Saakyan, R.; Sacerdoti, S.; Safford, T.; Sahu, N.; Sala, P.; Samios, N.; Sanchez, M.C.; Sanders, D.A.; Sankey, D.; Santana, S.; Santos-Maldonado, M.; Saoulidou, N.; Sapienza, P.; Sarasty, C.; Sarcevic, I.; Savage, G.; Savinov, V.; Scaramelli, A.; Scarff, A.; Scarpelli, A.; Schaffer, T.; Schellman, H.; Schlabach, P.; Schmitz, D.; Scholberg, K.; Schukraft, A.; Segreto, E.; Sensenig, J.; Seong, I.; Sergi, A.; Sergiampietri, F.; Sgalaberna, D.; Shaevitz, M.H.; Shafaq, S.; Shamma, M.; Sharma, H.R.; Sharma, R.; Shaw, T.; Shepherd-Themistocleous, C.; Shin, S.; Shooltz, D.; Shrock, R.; Simard, L.; Simos, N.; Sinclair, J.; Sinev, G.; Singh, J.; Singh, J.; Singh, V.; Sipos, R.; Sippach, F.W.; Sirri, G.; Sitraka, A.; Siyeon, K.; Smargianaki, D.; Smith, A.; Smith, A.; Smith, E.; Smith, P.; Smolik, J.; Smy, M.; Snopok, P.; Nunes, M.S.; Sobel, H.; Soderberg, M.; Salinas, C.J.S.; Söldner-Rembold, S.; Solomey, N.; Solovov, V.; Sondheim, W.E.; Sorel, M.; Soto-Oton, J.; Sousa, A.; Soustruznik, K.; Spagliardi, F.; Spanu, M.; Spitz, J.; Spooner, N.J.C.; Spurgeon, K.; Staley, R.; Stancari, M.; Stanco, L.; Steiner, H.M.; Stewart, J.; Stillwell, B.; Stock, J.; Stocker, F.; Stokes, T.; Strait, M.; Strauss, T.; Striganov, S.; Stuart, A.; Summers, D.; Surdo, A.; Susic, V.; Suter, L.; Sutera, C.M.; Svoboda, R.; Szczerbinska, B.; Szelc, A.M.; Talaga, R.; Tanaka, H.A.; Oregui, B.T.; Tapper, A.; Tariq, S.; Tatar, E.; Tayloe, R.; Teklu, A.M.; Tenti, M.; Terao, K.; Ternes, C.A.; Terranova, F.; Testera, G.; Thea, A.; Thompson, J.L.; Thorn, C.; Timm, S.C.; Tonazzo, A.; Torti, M.; Tortola, M.; Tortorici, F.; Totani, D.; Toups, M.; Touramanis, C.; Trevor, J.; Trzaska, W.H.; Tsai, Y.T.; Tsamalaidze, Z.; Tsang, K.V.; Tsverava, N.; Tufanli, S.; Tull, C.; Tyley, E.; Tzanov, M.; Uchida, M.A.; Urheim, J.; Usher, T.; Vagins, M.R.; Vahle, P.; Valdiviesso, G.A.; Valencia, E.; Vallari, Z.; Valle, J.W.F.; Vallecorsa, S.; Van Berg, R.; Van de Water, R.G.; Forero, D.V.; Varanini, F.; Vargas, D.; Varner, G.; Vasel, J.; Vasseur, G.; Vaziri, K.; Ventura, S.; Verdugo, A.; Vergani, S.; Vermeulen, M.A.; Verzocchi, M.; de Souza, H.V.; Vignoli, C.; Vilela, C.; Viren, B.; Vrba, T.; Wachala, T.; Waldron, A.V.; Wallbank, M.; Wang, H.; Wang, J.; Wang, Y.; Wang, Y.; Warburton, K.; Warner, D.; Wascko, M.; Waters, D.; Watson, A.; Weatherly, P.; Weber, A.; Weber, M.; Wei, H.; Weinstein, A.; Wenman, D.; Wetstein, M.; While, M.R.; White, A.; Whitehead, L.H.; Whittington, D.; Wilking, M.J.; Wilkinson, C.; Williams, Z.; Wilson, F.; Wilson, R.J.; Wolcott, J.; Wongjirad, T.; Wood, K.; Wood, L.; Worcester, E.; Worcester, M.; Wret, C.; Wu, W.; Wu, W.; Xiao, Y.; Yang, G.; Yang, T.; Yershov, N.; Yonehara, K.; Young, T.; Yu, B.; Yu, J.; Zaki, R.; Zalesak, J.; Zambelli, L.; Zamorano, B.; Zani, A.; Zazueta, L.; Zeller, G.P.; Zennamo, J.; Zeug, K.; Zhang, C.; Zhao, M.; Zhivun, E.; Zhu, G.; Zimmerman, E.D.; Zito, M.; Zucchelli, S.; Zuklin, J.; Zutshi, V.; Zwaska, R.The sensitivity of the Deep Underground Neutrino Experiment (DUNE) to neutrino oscillation is determined, based on a full simulation, reconstruction, and event selection of the far detector and a full simulation and parameterized analysis of the near detector. Detailed uncertainties due to the flux prediction, neutrino interaction model, and detector effects are included. DUNE will resolve the neutrino mass hierarchy to a precision of 5, for all values, after 2 years of running with the nominal detector design and beam configuration. It has the potential to observe charge-parity violation in the neutrino sector to a precision of 3 (5) after an exposure of 5 (10) years, for 50\% of all values. It will also make precise measurements of other parameters governing long-baseline neutrino oscillation, and after an exposure of 15 years will achieve a similar sensitivity to to current reactor experiments.This work was supported by CNPq, FAPERJ, FAPEG and FAPESP, Brazil; CFI, IPP and NSERC, Canada; CERN; MŠMT, Czech Republic; ERDF, H2020-EU and MSCA, European Union; CNRS/IN2P3 and CEA, France; INFN, Italy; FCT, Portugal; NRF, South Korea; CAM, Fundación “La Caixa” and MICINN, Spain; SERI and SNSF, Switzerland; TÜBİTAK, Turkey; The Royal Society and UKRI/STFC, UK; DOE and NSF, United States of America. This research used resources of the National Energy Research Scientific Computing Center (NERSC), a U.S. Department of Energy Office of Science User Facility operated under Contract No. DE-AC02-05CH11231
Oxidative Stress and Mitochondrial Injury in Chronic Multisymptom Conditions: From Gulf War Illness to Autism Spectrum Disorder
No full textBackground: Overlapping chronic multisymptom illnesses (CMI) include Chronic Fatigue Syndrome (CFS), fibromyalgia, irritable bowel syndrome, multiple chemical sensitivity, and Gulf War illness (GWI), and subsets of autism spectrum disorder (ASD). GWI entails a more circumscribed set of experiences that may provide insights of relevance to overlapping conditions.
Objectives: To consolidate evidence regarding a role for oxidative stress and mitochondrial dysfunction (OSMD), as primary mediators in CMI, using GWI as a departure point.
Methods: Exposure relations, character, timecourse and multiplicity of symptoms, and objective correlates of GWI are compared to expectation for OSMD. Objective correlates of OSMD in GWI and overlapping conditions are examined. 
Discussion: OSMD is an expected consequence of known GWI exposures; is compatible with symptom characteristics observed; and accords with objective markers and health conditions linked to GWI, extending to autoimmune disease and infection. Emergent triangulating evidence directly supports OSMD in multisymptom “overlap” CMI conditions, with similarities to, and diagnosed at elevated rates in, GWI, suggesting a common role in each. 
Conclusions: GWI is compatible with a paradigm by which uncompensated exposure to oxidative/nitrative stressors accompanies and triggers mitochondrial dysfunction, cell energy compromise, and multiple downstream effects such as vulnerability to autoantibodies. This promotes a profile of protean symptoms with variable latency emphasizing but not confined to energy-demanding post-mitotic tissues, according with (and accounting for) known properties of multisystem overlap conditions. This advances understanding of GWI; health conditions attending GWI at elevated rates; and overlap conditions like CFS and ASD, providing prospects for vulnerability assessment, mitigation of progression, treatment, and future prevention – with implications germane to additive and excessive environmental oxidative stressor exposures in the civilian setting.

Low exposure long-baseline neutrino oscillation sensitivity of the DUNE experiment
No full textThe Deep Underground Neutrino Experiment (DUNE) will produce world-leading neutrino oscillation measurements over the lifetime of the experiment. In this work, we explore DUNE's sensitivity to observe charge-parity violation (CPV) in the neutrino sector, and to resolve the mass ordering, for exposures of up to 100 kiloton-megawatt-calendar years (kt-MW-CY), where calendar years include an assumption of 57% accelerator uptime based on past accelerator performance at Fermilab. The analysis includes detailed uncertainties on the flux prediction, the neutrino interaction model, and detector effects. We demonstrate that DUNE will be able to unambiguously resolve the neutrino mass ordering at a 4σ (5σ) level with a 66 (100) kt-MW-CY far detector exposure, and has the ability to make strong statements at significantly shorter exposures depending on the true value of other oscillation parameters, with a median sensitivity of 3σ for almost all true δCP values after only 24 kt-MW-CY. We also show that DUNE has the potential to make a robust measurement of CPV at a 3σ level with a 100 kt-MW-CY exposure for the maximally CP-violating values δCP=±π/2. Additionally, the dependence of DUNE's sensitivity on the exposure taken in neutrino-enhanced and antineutrino-enhanced running is discussed. An equal fraction of exposure taken in each beam mode is found to be close to optimal when considered over the entire space of interest. © 2022 authors. Published by the American Physical Society. Published by the American Physical Society under the terms of the "https://creativecommons.org/licenses/by/4.0/"Creative Commons Attribution 4.0 International license. Further distribution of this work must maintain attribution to the author(s) and the published article's title, journal citation, and DOI. Funded by SCOAP3
Doping Liquid Argon with Xenon in ProtoDUNE Single-Phase: Effects on Scintillation Light
No full textDoping of liquid argon TPCs (LArTPCs) with a small concentration of xenon is a technique for light-shifting and facilitates the detection of the liquid argon scintillation light. In this paper, we present the results of the first doping test ever performed in a kiloton-scale LArTPC. From February to May 2020, we carried out this special run in the single-phase DUNE Far Detector prototype (ProtoDUNE-SP) at CERN, featuring 720 t of total liquid argon mass with 410 t of fiducial mass. A 5.4 ppm nitrogen contamination was present during the xenon doping campaign. The goal of the run was to measure the light and charge response of the detector to the addition of xenon, up to a concentration of 18.8 ppm. The main purpose was to test the possibility for reduction of non-uniformities in light collection, caused by deployment of photon detectors only within the anode planes. Light collection was analysed as a function of the xenon concentration, by using the pre-existing photon detection system (PDS) of ProtoDUNE-SP and an additional smaller set-up installed specifically for this run. In this paper we first summarize our current understanding of the argon-xenon energy transfer process and the impact of the presence of nitrogen in argon with and without xenon dopant. We then describe the key elements of ProtoDUNE-SP and the injection method deployed. Two dedicated photon detectors were able to collect the light produced by xenon and the total light. The ratio of these components was measured to be about 0.65 as 18.8 ppm of xenon were injected. We performed studies of the collection efficiency as a function of the distance between tracks and light detectors, demonstrating enhanced uniformity of response for the anode-mounted PDS. We also show that xenon doping can substantially recover light losses due to contamination of the liquid argon by nitrogen.36 pages, 20 figures. Corrected author list; corrected typos across paper and polished tex
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
No full textBackground: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Methods: This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018. Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and received patisiran 0·3 mg/kg by intravenous infusion every 3 weeks with plans to continue to do so for up to 5 years. Efficacy assessments included measures of polyneuropathy (modified Neuropathy Impairment Score +7 [mNIS+7]), quality of life, autonomic symptoms, nutritional status, disability, ambulation status, motor function, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2 OLE patisiran) based on allocation in the parent trial. The global OLE is ongoing with no new enrolment, and current findings are based on the interim analysis of the patients who had completed 12-month efficacy assessments as of the data cutoff. Safety analyses included all patients who received one or more dose of patisiran up to the data cutoff. This study is registered with ClinicalTrials.gov, NCT02510261. Findings: Between July 13, 2015, and Aug 21, 2017, of 212 eligible patients, 211 were enrolled: 137 patients from the APOLLO-patisiran group, 49 from the APOLLO-placebo group, and 25 from the phase 2 OLE patisiran group. At the data cutoff on Sept 24, 2018, 126 (92%) of 137 patients from the APOLLO-patisiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE patisiran group had completed 12-month assessments. At 12 months, improvements in mNIS+7 with patisiran were sustained from parent study baseline with treatment in the global OLE (APOLLO-patisiran mean change –4·0, 95 % CI –7·7 to −0·3; phase 2 OLE patisiran –4·7, –11·9 to 2·4). Mean mNIS+7 score improved from global OLE enrolment in the APOLLO-placebo group (mean change from global OLE enrolment −1·4, 95% CI –6·2 to 3·5). Overall, 204 (97%) of 211 patients reported adverse events, 82 (39%) reported serious adverse events, and there were 23 (11%) deaths. Serious adverse events were more frequent in the APOLLO-placebo group (28 [57%] of 49) than in the APOLLO-patisiran (48 [35%] of 137) or phase 2 OLE patisiran (six [24%] of 25) groups. The most common treatment-related adverse event was mild or moderate infusion-related reactions. The frequency of deaths in the global OLE was higher in the APOLLO-placebo group (13 [27%] of 49), who had a higher disease burden than the APOLLO-patisiran (ten [7%] of 137) and phase 2 OLE patisiran (0 of 25) groups. Interpretation: In this interim 12-month analysis of the ongoing global OLE study, patisiran appeared to maintain efficacy with an acceptable safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Continued long-term follow-up will be important for the overall assessment of safety and efficacy with patisiran. Funding: Alnylam Pharmaceuticals
